Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
bendamustine (treanda) (1 trial)
everolimus (zortress) (2 trials)
lbh581 (1 trial)
ofatumumab (arzerra) (1 trial)
panitumumab (vectibix) (1 trial)
sorafenib (nexavar) (1 trial)
urea (1 trial)
carboplatin (paraplatin) (1 trial)
doxorubicin (Doxil) (1 trial)
lenalidomide (revlimid) (1 trial)
namitecan (1 trial)
paclitaxel (taxol) (1 trial)
panobinostat (farydak) (1 trial)
satraplatin (1 trial)
vinorelbine (navelbine) (1 trial)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Trials (9 total)
Trial APIs (15 total)